Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — if pharmaceutical companies would allow it. https://t.co/p6z3ajkmUw ...

[Music] I thank the organizers for this beautiful wonderful program. Uh thank you so much uh director sir and his team. Um my father Shri Babradesh pan uh he was a freedom fighter.He lived more than 100 years and uh father had very beautiful connections. So I have utilized maximum uh with that I'm here with you all today. Connections are very very important in life.uh he was well connected with politicians and the business people all the social workers in Kaluri. Uh my mother Shrimati Ratama she sold the ve ...

Core Insights - Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, and its CEO has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London [1][2] Company Overview - Allarity Therapeutics is dedicated to developing personalized cancer treatments, particularly stenoparib for advanced ovarian cancer patients, utilizing its Drug Response Predictor (DRP) technology [5] - The company has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [3] Drug Information - Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential therapeutic action against various cancers, including ovarian cancer [3] - The DRP companion diagnostic platform is designed to select patients likely to benefit from specific drugs based on gene expression signatures, enhancing therapeutic benefit rates [4] Conference Participation - CEO Thomas Jensen will present a talk titled "A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib" at the conference on October 1, 2025, and will be available for individual meetings to discuss business development opportunities [6][8]

Core Insights - The article highlights that small-cap biotech companies often attract attention for fundraising and partnerships, but occasionally the focus shifts to their scientific advancements [1] Company and Industry Summary - Small-cap biotech companies are frequently in the news for their fundraising efforts and strategic partnerships, which are critical for their growth and development [1] - The scientific progress made by these companies can sometimes take precedence over financial activities, indicating the importance of innovation in the biotech sector [1]

Core Insights - NovoCure's mission is to extend survival in aggressive cancer forms through Tumor Treating Fields technology [2] - The company is transitioning from a single indication focus, primarily on GBM, which generates $600 million in revenue, to a multi-indication platform [3] - By the end of 2026, NovoCure aims to have four products, creating a diversified revenue stream and a clear path to profitability [3]

New research suggests that encouraging the growth of healthy cells may prevent the spread of cancerous ones. We explain how that could be game-changing for treatments https://t.co/FQXBRX2QcA ...

The odds didn’t look good when Gwen Orilio was diagnosed with stage-four lung cancer. Ten years later, she’s still alive—and part of a new era of cancer treatment. https://t.co/kDrGYeJsWf ...

#tedxmaharashtracollege #MaharashtraCollege #DrwasimPhoplunkar #oncologist Dr. Wasim S. Phoplunkar is a globally acclaimed Radiation Oncologist , with 25+ years of global experience across India, Canada and Saudi Arabia. From cutting-edge treatments like IMRT, IGRT & RapidArc to humanizing the cancer care journey, Dr. Phoplunkar is redefining healing with both technology and compassion This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn ...

Core Viewpoint - Iovance Biotherapeutics, despite its innovative drug Amtagvi for advanced melanoma, faces challenges in stock performance and operational execution [1][2]. Company Overview - Iovance Biotherapeutics is a small-cap biotech company known for developing Amtagvi, the first approved treatment for advanced melanoma [1]. - The manufacturing and administration process of Amtagvi is complex, requiring tumor samples from patients to extract T cells for lab growth, followed by patient-specific infusions [4]. Financial Performance - In Q2, Iovance reported approximately $60 million in revenue, nearly double from the previous year, primarily driven by Amtagvi sales [6]. - For fiscal 2025, the company anticipates total product revenue between $250 million and $300 million, predominantly from Amtagvi [6]. Market Potential - Amtagvi is expected to gain approval in additional regions, including Canada and Europe, within the next 12 months, potentially expanding the market significantly [7]. - The U.S. market for Amtagvi remains largely untapped, with only over 100 patients treated compared to the 8,000 annual melanoma deaths [8]. - There are opportunities for label expansions into other cancer indications, which could further increase the target market for Amtagvi [9]. Challenges - The complex and costly nature of Amtagvi poses challenges for Iovance in achieving profitability and market traction [10]. - The company ended Q2 with approximately $307 million in cash, which is projected to last until Q4 of the following year, indicating potential financial strain [11]. - Clinical and regulatory hurdles could negatively impact the stock price and overall company performance [12].

The odds didn’t look good when Gwen Orilio was diagnosed with stage-four lung cancer. Ten years later, she’s still alive—and part of a new era of cancer treatment. https://t.co/EcrVz0OWSe ...